Portfolio companies news

13 May 2016

Tobira Therapeutics Announces Publication of Phase 1 Study Results Showing Cenicriviroc Safety in Cirrhotic Patients

Tobira Therapeutics, Inc.  ( NASDAQ : TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today announced that data from a study of cenicriviroc (CVC) in participants with liver cirrhosis and mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment, has been accepted as a manuscript for publication in the journal Clinical Translational Science. 

10 May 2016

Tobira Therapeutics Reports First Quarter 2016 Financial and Business Result

Tobira Therapeutics, Inc.  ( NASDAQ : TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today reported business highlights and financial results for the three months ended  March 31, 2016.

03 May 2016

Celtaxsys Begins EU Enrollment for CF Lung Function Preservation Trial of Acebilustat Anti-Inflammatory Therapy for Cystic Fibrosis

Celtaxsys, a clinical stage drug development company focused on advancing therapies for patients with rare and orphan inflammatory diseases, announced today the opening of enrollment in Europe of an international phase 2 clinical trial for acebilustat, its flagship treatment for people with cystic fibrosis (CF).

02 May 2016

Tobira Announces Interim 12-week Results from the ORION Study

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced top-line results from a 12-week interim analysis of the Phase 2a ORION study showing that treatment with cenicriviroc (CVC) in obese patients with prediabetes or diabetes and fatty liver disease was well tolerated and associated with improvements in insulin sensitivity.

02 May 2016

Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2016 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update and reported its financial results for the quarter ended March 31, 2016.

26 April 2016

Clearside Biomedical, Inc. Announces Positive Preliminary Phase 2 Results in Patients With Macular Edema Associated with Retinal Vein Occlusion

Сlearside Biomedical, Inc. today announced that its Phase 2 clinical trial evaluating concomitant administration of suprachoroidal ZUPRATA™, Clearside’s proprietary form of triamcinolone acetonide, together with intravitreal aflibercept (EYLEA®), for the treatment of macular edema associated with retinal vein occlusion (RVO), achieved its primary endpoint.

19 April 2016

Marinus Pharmaceuticals’ Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented preclinical data of ganaxolone IV, the Company’s intravenous formulation of its CNS-selective GABA_A modulator,  showing robust activity in a well-accepted and clinically translatable animal model of status epilepticus (SE). The data were presented during an oral and poster presentations at the 68^th American Academy of Neurology (AAN) Annual Meeting in Vancouver, BC, Canada, April 15-21, 2016.

15 April 2016

Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the intravenous (IV) formulation of its CNS-selective GABAAmodulator, ganaxolone, for the treatment of status epilepticus. A Phase 1 clinical trial evaluating the safety, tolerability and pharmacokinetics of ganaxolone IV is expected to initiate in the first half of 2016.

11 April 2016

Tobira Therapeutics and Dong-A ST Enter Into License Agreements for Evogliptin and Cenicriviroc

Tobira Therapeutics, Inc. (NASDAQ:TBRA) and Dong-A ST Co., Ltd. (170900: Korea SE), today announced that the companies have entered into two separate licensing agreements. Tobira has acquired exclusive rights to develop and market evogliptin in combination with cenicriviroc (CVC) and as a single agent in the United States, Canada, Europe and Australia for all therapeutic indications. 

15 March 2016

Atlas Genetics wins SBRI grant from Innovate UK

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the ultra-rapid Point-Of-Care (POC) molecular diagnostics company, today announces that it has been awarded an SBRI grant from Innovate UK to assist in the development of an ultra-rapid POC multiplex STI test measuring the four most commonly occurring pathogens (Chlamydia trachomatis, Neisseria gonorrhoea, Trichomonas vaginalis and Mycoplasma genitalium) in less than 30 minutes.